We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Bladder Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Bahram Mofid
Apr 30, 2021
1-yes & nephrectomy is effective on overall survival
2_ciplatin base if GFR is more than 60
3_l don't know
4_immunotherapy
Guru Sonpavde
May 16, 2021
A large papillary urothelial carcinoma (low grade disease is unlikely to be locally advanced and metastatic and I would get pathology second opinion) of the upper tract with primarily squamous differentiation and likely metastatic disease (adrenal) qualifies for surgery if possible, but systemic chemotherapy with neoadjuvant intent is reasonable in this case if complete excision looks difficult currently. The adrenal lesion is likely to be a metastasis but would get a biopsy to clarify- obviously, if this is a metastasis, therapy would involve systemic chemotherapy in the neoadjuvant or adjuvant setting. The caveat is that the efficacy of systemic therapy in predominant squamous cell carcinoma appears suboptimal and current therapy in the real world extrapolates data from urothelial/predominant urothelial carcinoma enrolled in most trials (i.e cisplatin-gemcitabine [GC] or dose dense MVAC). Off-trial and in settings where a better response rate may improve the probability of complete excision, I have considered paclitaxel added to GC or dose dense MVAC rather than standard GC in the neoadjuvant intent setting (since firstline metastatic disease trials in urothelial carcinoma suggest better response rates for these strategies [albeit without definitively improved long-term outcomes -although dose-dense MVAC did improve survival in one underpowered randomized trial compared to standard MVAC]). There are no biomarkers to guide firstline therapy, but genomic profiling for FGFR3/2 is important especially since upper tract carcinoma is more likely to harbor them (erdafitinib is approved for post-platinum therapy at progression). If complete surgical resection before or after chemotherapy is not possible, I would offer switch maintenance avelumab if stable or responding to chemotherapy. Further future options include enfortumab vedotin, erdafitinib (if FGFR2/3 mutations/fusions), sacitizumab govitecan and trials.
Dec 26, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Bahram Mofid
Apr 30, 2021
Guru Sonpavde
May 16, 2021
Dec 26, 2024
Pending Moderator approval.